ULTRAGENYX PHARMACEUTICAL IN (RARE) Stock Cash Flow
NASDAQ:RARE - Nasdaq - US90400D1081 - Common Stock - Currency: USD
| 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net Income | -569.18M | -606.64M | -707.42M | -454.03M | -186.57M | |||
| Depreciation Amortization | 35.54M | 26.01M | 18.22M | 13.24M | 12.26M | |||
| Income Taxes - Deferred | 0.00 | -1.62M | -1.64M | 0.00 | N/A | |||
| Change In Working Capital | 13.92M | -13.48M | 61.87M | -63.24M | 104.66M | |||
| Other non cash items | 105.53M | 120.93M | 248.50M | 165.33M | -62.58M | |||
| OPERATING CASH FLOW | -414.19M | -474.81M | -380.47M | -338.70M | -132.22M | |||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Capital Expenditure | -19.99M | -46.77M | -146.12M | -73.09M | -43.91M | |||
| Other Investing Activity | 2.22M | 214.77M | -145.53M | -122.28M | -135.22M | |||
| INVESTING CASH FLOW | -17.77M | 168.00M | -291.65M | -195.37M | -179.12M | |||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Debt Issued/Reduced | N/A | N/A | N/A | N/A | N/A | |||
| Stock Issued/Repurchased | 392.24M | 388.17M | 10.81M | 119.04M | 600.51M | |||
| Dividend Paid | N/A | N/A | N/A | N/A | N/A | |||
| Other Financing Activity | 7.00M | -28.00K | 490.40M | -490.00K | -240.00K | |||
| FINANCING CASH FLOW | 399.24M | 388.14M | 501.21M | 118.55M | 600.27M | |||
| Exchange Rate Effect | -2.52M | 462.00K | -1.08M | -1.19M | 1.12M | |||
| CHANGE IN CASH | -35.24M | 81.80M | -171.99M | -416.71M | 290.05M | |||
| FREE CASH FLOW | ||||||||
| Operating Cash Flow | -414.19M | -474.81M | -380.47M | -338.70M | -132.22M | |||
| Capital Expenditure | -19.99M | -46.77M | -146.12M | -73.09M | -43.91M | |||
| FREE CASH FLOW | -434.18M | -521.57M | -526.59M | -411.79M | -176.13M | |||
All data in USD